No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Kangmei Pharmaceutical (SHSE:600518) Investors Are Sitting on a Loss of 34% If They Invested Five Years Ago
Is Kangmei Pharmaceutical Co., Ltd.'s (SHSE:600518) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Kangmei Pharmaceutical Co., Ltd. (SHSE:600518) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Kangmei Pharmaceutical (SHSE:600518 Investor Three-year Losses Grow to 49% as the Stock Sheds CN¥1.2b This Past Week
Kangmei Pharmaceutical (600518.SH): Not currently involved in AI medicine.
Kangmei Pharmaceutical (600518.SH) stated on the interactive platform on November 22 that the business of the company does not currently involve AI medicine.
